Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

BioAge just completed its IPO to continue funding clinical trials, but competition will be stiff. BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Well, a little-known biopharmaceutical company called BioAge Labs (NASDAQ: BIOA) is looking to bring a new spin to the weight loss space, and it just completed its initial public offering (IPO).

BioAge Labs raised $238.3 million in its IPO. Moreover, the company's S-1 Filing shows that operating expenses were $28.1 million through the first six months of 2024 -- implying an annual run ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...